Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development INDIANAPOLIS, June 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and i ...

Although there is no hard-and-fast rule about what constitutes a blue-chip stock, they all tend to have certain qualities. They are large, financially stable companies that have been through numerous business and economic cycles that proved their worth in the end.The upper echelon of the S&P 500 are the sort of stocks that comprise blue-chip stocks. Yet investors need to be careful because “blue-chip” doesn’t always mean the same thing to everyone. The T. Rowe Price Blue Chip Growth ETF (NYSEARCA:TCHP), for ...

A month has gone by since the last earnings report for Eli Lilly (LLY) . Shares have added about 4.5% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Lilly due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Q1 Earnings Top, Sales In Line, 2024 View RaisedLilly report ...

Today, Eli Lilly's market value tops $700 billion.Companies with a trillion-dollar market value have several key things in common. They have a track record of earnings growth, sell products or services people depend on, and their prospects for future growth look bright. Great examples are Microsoft, Apple, and Amazon -- valued at $3.1 trillion, $2.9 trillion, and $1.8 trillion, respectively. These trillion-dollar companies also happen to be operating in the technology industry, one that's known for growth a ...

New $6.5 million commitment will help strengthen systems to improve health outcomes across resource-limited areas in India GENEVA, May 29, 2024 /PRNewswire/ -- During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF to expand UNICEF's work to improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India. This will bring the compa ...

INDIANAPOLIS, May 28, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Patrik Jonsson, executive vice president, president of Lilly Diabetes and Obesity, and president of Lilly USA, will participate in a fireside chat at 4 p.m. Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations. ...

Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.Eli Lilly (LLY -0.13%) stock is already up by about 90% over the past year, and it could climb even higher. BMO Capital analyst Evan Seigerman recently raised his price target to $1,001 per share, which implies a gain of about 24% from recent prices.Seigerman recently noted that soaring demand for Eli Lilly's weight management drug, Zepbound, is outpacing supply. The company plans to improve on the ...

Company Investment and Expansion - Eli Lilly and Company is increasing its investment in its manufacturing site in Lebanon, IN, from $3.7 billion to $9 billion, allowing for enhanced capacity to manufacture active pharmaceutical ingredients for its tirzepatide drugs, Mounjaro and Zepbound [1] - The investment will create 200 new jobs for highly skilled workers and 5,000 construction jobs during development, with drug manufacturing expected to begin by the end of 2026 and production increasing through 2028 [1] Product Performance - Mounjaro and Zepbound have generated significant revenue, with Mounjaro bringing in $1.81 billion and Zepbound $517.4 million in the first quarter of 2024 [2] - Both drugs utilize the compound tirzepatide, which is gaining popularity in the GLP-1 drug segment for treating multiple cardiometabolic diseases [2] Supply and Demand Dynamics - There is a supply shortage for Mounjaro and Zepbound, with demand exceeding supply despite increased production volumes [5] - Lilly has committed over $18 billion since 2020 to enhance manufacturing capabilities in the U.S. and Europe, expecting a meaningful increase in shipment volumes from the second half of 2024 [5] Market Outlook and Competition - Lilly raised its sales and earnings guidance for 2024 due to strong demand for its products and confidence in production expansion plans [6] - The obesity medicine market is expanding due to rising global health concerns, with competition from Novo Nordisk's semaglutide and other companies like Viking Therapeutics and Amgen developing similar products [6][7]

Core Viewpoint - Eli Lilly's shares have reached all-time highs, driven by strong fundamentals and market hype surrounding the obesity market, particularly related to GLP-1 drugs [2] Group 1: Financial Performance and Guidance - Eli Lilly raised its full-year revenue guidance by $2 billion to a range of $42.4-43.6 billion, reflecting a 26% year-over-year growth [3] - The non-GAAP EPS guidance was increased from $12.20-12.70 to $13.50-14.00, driven by the increased revenue growth guidance [3] - The growth of the incretin business remains supply constrained, but management is optimistic about easing supply constraints in the second half of the year [3][4] Group 2: Competitive Positioning - Eli Lilly is catching up to Novo Nordisk in the obesity market, but both companies face supply constraints that affect market share dynamics [4] - Eli Lilly's tirzepatide shows better efficacy compared to Novo Nordisk's semaglutide, with a head-to-head trial expected to provide further validation [5] - Eli Lilly has positive phase 3 results for tirzepatide in obstructive sleep apnea and is awaiting results for heart failure trials, which could expand its market label [5] Group 3: Pipeline and Future Growth - Eli Lilly has a robust pipeline beyond obesity, including candidates for atopic dermatitis and Alzheimer's disease, which could drive near-term growth [6] - The company is also exploring RNAi candidates and has plans for M&A to strengthen its competitive position in the obesity market [7] - Eli Lilly's acquisition of bimagrumab aims to address muscle mass loss associated with weight loss treatments, indicating a proactive approach to market challenges [5][7] Group 4: Market Dynamics and Risks - The obesity market is highly competitive, with many emerging companies, but Eli Lilly and Novo Nordisk currently dominate the commercial landscape [5] - Supply constraints for tirzepatide and semaglutide are expected to persist, impacting growth potential in the near term [3][5] - Eli Lilly's elevated valuation requires consistent growth to maintain shareholder value, with risks associated with potential M&A activities [11]

Core Investment Thesis - Investing in pharmaceutical stocks can yield significant returns if the right companies are selected and held long-term [1] Vertex Pharmaceuticals - Vertex Pharmaceuticals dominates the cystic fibrosis (CF) market, generating nearly $2.7 billion in sales in Q1, a 13% increase year-over-year [2][3] - The company has a strategy to access nearly all eligible CF patients and is developing additional therapies, minimizing R&D costs [2] - Vertex is also seeking FDA approval for its acute pain program, which could provide substantial revenue if successful, while its CF business remains a strong fallback [3] Eli Lilly - Eli Lilly is focused on cardiometabolic medicines, with its drugs Mounjaro and Zepbound generating significant sales, $1.8 billion and $517 million respectively in Q1 [4][5] - The company is in the process of developing new molecules for type 2 diabetes and obesity, and expanding indications for existing drugs to meet high demand [5] - Eli Lilly's production capabilities are currently unable to meet demand, indicating a bullish outlook for the stock as it works to catch up [5] Pfizer - Pfizer's strategy involves becoming a leader in oncology medicines through R&D, acquisitions, and collaborations, aiming for an additional $45 billion in annual revenue by 2030 [6][7] - The company expects 2024 revenue between $58.5 billion and $61.5 billion, potentially exceeding $100 billion annually by 2030 [7] - While ambitious, Pfizer's plans are supported by a history of successful execution, presenting a favorable risk-reward balance [7]